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Ten years risk assessment of atherosclerotic
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Asian sub-population
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Abstract
Background: Atherosclerotic cardiovascular diseases (ASCVD) are on the rise in low and middle-income countries
attributed to modern sedentary lifestyle and dietary habits. This has led to the need of assessment of the burden of
at-risk population so that prevention measures can be developed. The objective of this study was to assess ten
years risk assessment of ASCVD using Astro-CHARM and Pooled Cohort Equation (PCE) in a South Asian sub-
population.
Methods: A total of 386 residents of all six districts of Karachi with no ASCVD were enrolled in the study through
an exponential non-discriminative referral snowball sampling technique. The inclusion criteria consisted of age 40
years or above and either gender. Study participants were enrolled after obtaining informed written consent and
those study participants who were found to have either congenital heart disease or valvular heart diseases or
ischemic heart disease were excluded from the study based on initial screening. For the calculation of 10 years risk
of ACVD based on Astro-CHARM and PCE, the variables were obtained including medical history and coronary
artery calcium and C-reactive protein measurements.
Results: Mean estimated 10-year risk of fatal or non-fatal myocardial infarction or stroke as per the Astro-CHARM
was 13.98 ± 8.01%, while mean estimated 10-year risk of fatal or non-fatal myocardial infarction or stroke as per the
PCE was 22.26 ± 14.01%. Based on Astro-CHARM, 11.14% of the study participants were labeled as having high risk,
while PCE estimated 20.73% of study participants as having high risk of ASCVD.
Conclusion: Despite the fact that our findings showed substantial differences in ten-year risk of ASCVD between
Astro-CHARM and PCE, both calculators can be used to develop a new population and specific risk estimators for
this South Asian sub-population. Our study provides the first step towards developing a risk assessment guided
decision-making protocol for primary prevention of ASCVD in this population.
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Background
With the ever-increasing global burden of atherosclerotic
cardiovascular diseases (ACVD) the need to timely assess
the risk of cardiovascular events cannot be more empha-
sized [1–5]. Once among the most common causes of
death in high-income countries only, ACVD has become
the leading cause of morbidity and mortality in low and
middle-income countries as well owing to epidemiologic
transition and changing population dynamics. This trend
is more prominent in the South Asian population where
(ACVD) is the leading cause of death [6, 7].
A number of risk estimators have been developed to
assess the risk of any cardiovascular event in at-risk
population. Astro-CHARM and Pooled Cohort Equation
(PCE) has been much widely used worldwide however
these estimators have been developed in the west and
not much evidence is present that how accurately they
estimate ACVD in South Asian population [8, 9]. Tariq
et al. [10] reported that the Pakistani population showed
to have a higher risk of ASCVD compared to whites,
blacks, and Hispanic and even South Asians living in
USA. Another study conducted in a similar population
showed that the burden of premature myocardial infarc-
tion to be as high as 12% [11]. In addition, another large
multi-centric study from Pakistan attempted to predict
the risk of atherosclerotic cardiovascular disease in Paki-
stani population, however, included subject with already
suffered from ASCVD [12]. Such methodological flaws
can have serious implications while projecting risk as-
sessment on the general population. There is a scarcity
of literature providing estimates of ASCVD risk in resi-
dent South Asian population as well as comparison of
different risk estimators in this population.
Majority of these studies have used PCE as a risk esti-
mator which has its own limitation that includes over-
estimating the risk in other nationalities/ ethnicities and
in population with less social deformation which re-
quires attention while making medical decisions. To
overcome this Astro-CHARM calculation was used
(Astronaut Cardiovascular Health and Risk Modifica-
tion). Data in white, Hispanic & black have been eluci-
dated except for the South Asians [8].
Cardiovascular risk can be estimated as either abso-
lute, relative, lifetime, or recurrent. An internationally
agreed-upon guidelines do not exist in this regard [13].
The 10 years risk of coronary events (high, intermediate,
or low) can be determined by various risk scores, such
as laboratory and non-laboratory Framingham risk score
for CVD, systematic coronary risk evaluation, Reynolds
risk score, the Lancet chronic diseases risk charts, World
Health Organization risk charts, etc., but poor concord-
ance has been reported between the risk score, jeopard-
izing their clinical utility [14]. ACC/AHA preventive
guidelines advocate the use of PCE for the assessment of
cardiovascular risk [15] and Astro-CHARM is consid-
ered to be a significant improvement over the PCE with
the addition of discriminating power of coronary ar-
tery calcium (CAC) and hs-CRP [8]. Keeping in mind
the ease of adoption of PCE in a resource-limited setting
and predictive superiority of Astro-CHARM, we assessed
the risk of ASCVD in our population using both
modalities.
This study, to the best of our knowledge, attempted to
estimate the ten-year risk of ASCVD in general popula-
tion without any history of ASCVD using both Astro-
CHARM and PCE, the aim of this study was to estimate
risk and compared both the modalities.
Methods
This analytical cross-sectional study was conducted
among 386 residents of all six districts of Karachi
who had no prior history of atherosclerotic cardiovas-
cular disease including stroke. Study was approved by
the ethical review committee of the National Institute
of Cardiovascular Diseases (NICVD) Karachi, Pakistan
(ERC-29/2018). Karachi is the largest metropolitan
city of the country with a diverse ethnic distribution,
inhabiting around 15 million people with a fair share
of all the ethnicities residing in the country. Due to
non-availability of the sampling frame for any prob-
ability sampling technique, non-probability snowball
sampling technique was adopted. Starting with the re-
cruitment of consenting individuals, for all six dis-
tricts of the city, meeting the inclusion criteria of the
study from healthy attendants visiting our center. The
exponential non-discriminative referral technique was
adopter where every recruited participant was allowed
multiple referrals from his/her acquaintances. All the
referrals were contacted and directed to a designated
desk at the doctor’s office for initial screening and as-
sessment. After a thorough history, physical, and elec-
trocardiographic assessment to rule out underlying
atherosclerotic cardiovascular disease, participants of
both gender and age between 40 to 65 years were in-
cluded in this study. Study participants were enrolled
after obtaining informed written consent and those
study participants who were found to have either
congenital heart disease or valvular heart diseases or
ischemic heart disease were excluded from the study
based on initial screening. Individuals who refused or
shown reluctance to accept computed tomography
angiography (CTA) or other laboratory assessments
such as lipid profile or C-reactive protein (hs-CRP)
were excluded after an initial assessment.
Fasting (12 h) lipid profile and hs-CRP level were ob-
tained for all the enrolled patients and for the calculation
of 10 years risk of ACVD based on Astro-CHARM and
PCE, the variables were obtained in the following manner.
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Diabetes mellitus, hypertension, current smoking, and
family history of heart attack were defined as per Astro-
CHARM definitions [8].
High-sensitivity C-reactive protein (hs-CRP) levels were
measured by using the following assays. MESA, BNII
nephelometer (N High Sensitivity CRP; Dade Behring
Inc); DHS, Roche/Hitachi 912 System, Tina-quant assay
(Roche Diagnostics), alatex-enhanced immunoturbidi-
metric method; PACC, particleenhancedimmune turbidi-
metric latex agglutination assay; FHS, enhanced immune
turbidimetric high-sensitivity assay (Roche Diagnostics).
Computed tomography angiography (CTA) was per-
formed in all the patients and coronary artery calcium
(CAC) score was calculated for all the patients.
Data were entered using MS Excel for Windows and ana-
lyses were done using STATA 11.0 while 10 years risk of
ACVD was calculated using Astro-CHARM and PCE using
the online calculators available at www.AstroCHARM.org
and www.clincalc.com respectively. Participants were strati-
fied as low-risk and high-risk individuals based on cut-off
have of ≥7.5% for both Astro-CHARM and PCE.
Descriptive analyses were conducted by calculating the
mean and standard deviation for all continuous variables
while frequency and percentages were calculated for all
categorical variables. Comparison between male and fe-
male participants on continuous variables was made by
performing independent sample t-test and categorical
variables were compared by applying Chi-square test
and p-value ≤0.05 as taken as criteria for statistical sig-
nificance. Risk of ACVD was reported using both equa-
tions for the combined study population and was also
stratified for different sub-groups.
Results
Mean age of the study participants was 49 ± 7.10 years
with 54% Males. Mean BMI was 28.11 ± 5.38 while 45.6,
15.8, and 14.2% were hypertensive, diabetics and current
smokers respectively. Six (2 %) of the study participants
had all three co-morbid conditions. Thirty percent had
positive family history of MI. Mean CAC was 7.50 ±
14.05 Agatston units. Table 1 shows the baseline socio-
demographic and medical characteristics of study parti-
cipants stratified by gender.
Mean estimated 10-year risk of fatal or non-fatal myo-
cardial infarction or stroke as per the Astro-CHARM
was 13.98 ± 8.01%, while mean estimated 10-year risk of
fatal or non-fatal myocardial infarction or stroke as per
the PCE was 22.26 ± 14.01%. Risk comparison in differ-
ent age categories showed a significantly higher risk of
ACVD in age groups of 55–60 years and 60 years and
above compared to the ASCVD risk in the age group
40–45 years as shown in Fig. 1.
Similarly, Table 2 below shows the comparison of
baseline characteristics of high and low-risk individuals








Age (years)a 49 ± 7.11 49.47 ± 7.24 48.43 ± 6.93 0.153
Body mass index (kg/m2)a 28.12 ± 5.39 26.93 ± 4.71 29.55 ± 5.8 < 0.001
Coronary artery calcium (Agatston units)a 31.57 ± 195.63 44.61 ± 253.95 15.86 ± 79.94 0.121
Total cholesterol (mg/dL)a 177.65 ± 38.97 174.91 ± 37.02 180.94 ± 41.07 0.131
HDL cholesterol (mg/dL)a 51.73 ± 36.78 50.93 ± 48.39 52.7 ± 12.85 0.639
Systolic blood pressure (mmHg)a 138.83 ± 21.23 135.73 ± 20.81 142.57 ± 21.18 0.002
Hypertensive
Yes 176 (45.6%) 78 (36.97%) 98 (56%) < 0.001
No 210 (54.4%) 133 (63.03%) 77 (44%)
Diabetic
Yes 61 (15.8%) 34 (16.11%) 27 (15.43%) 0.854
No 325 (84.2%) 177 (83.89%) 148 (84.57%)
Current Smoker
Yes 55 (14.25%) 50 (23.7%) 5 (2.86%) < 0.001
No 331 (85.75%) 161 (76.3%) 170 (97.14%)
Family History of Myocardial Infarction
Yes 118 (30.57%) 66 (31.28%) 52 (29.71%) 0.74
No 268 (69.43%) 145 (68.72%) 123 (70.29%)
a reported as mean and standard deviation, all other variables are reported as frequencies and percentages
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based on Astro-CHARM and Pooled Cohort Estimator.
Kappa agreement between the two calculators in terms
of labeling high and low-risk individuals was high (0.50,
p-value < 0.0001).
Out of 386 individuals, 8.8% (34) were categorized as
high risk by both Astro-CHARM and PCE and 76.9%
(297) were categorized as low risk by both Astro-
CHARM and PCE. Taking Astro-CHARM as gold stand-
ard for categorizing high risk individuals, PCE has sensi-
tivity of 79.07%, specificity of 86.59%, positive predictive
value of 42.50%, and negative predictive value of 97.06%,
as presented in Table 3.
Discussion
To the best of our knowledge, current study reports 10
year risk of ASCVD among non-cardiac Pakistani popu-
lation using both Astro-CHARM and PCE and the
comparison of the two calculators for the first time. In
concordance with the findings of other studies, PCE
estimated the risk of ASCVD in the study population
almost twice as that estimated by Astro-CHARM. Astro-
CHARM which also includes indicators like coronary
artery calcium and C-reactive protein during ASCVD
risk assessment, these indicators are not readily available
in low and middle-income countries, therefore, the
significance of PCE cannot be neglected [16].
One of the key findings of this study was that both
coronary artery calcium and C reactive protein signifi-
cantly correlated with the risk scores generated by PCE
which is in concordance with findings from other studies
[17, 18]. Especially in the case of CAC, a relatively recent
study by JJ Carr et al. [17] reported its effect on the risk
of ASCVD among individuals well below 40 years of age.
Keeping in mind that said study was conducted among
African-Americans and Caucasians, who are relatively at
lower risk of developing ASCVD compare to South
Asians, it points towards a major limitation of these risk
calculators among South Asians, who, in clinical experi-
ence suffer cardiac events at an even younger age [19]
and evidenced by the previous study from Pakistan [10],
there is a dire need of development of population-
specific risk estimator for the South Asian population.
This study provided the grounds towards developing
such risk estimator as well as initial step towards devel-
oping evidence-based decision making for primary pre-
vention guidelines of atherosclerotic cardiovascular
disease in this population.
Considering the fact that the population of South
Asian countries consists of multi-ethnical groups with
possibly different inherent risk of developing ASVD, as
well as the absence of risk estimators in population
below 40 years of age much evidence is required to de-
velop population-specific risk estimators and risk guided
decision-making tools for primary prevention among
South Asians using robust study designs. Furthermore,
considering the sub-optimal healthcare systems and the
absence of expensive investigating facilities like CAC in
low and middle-income countries of South Asia, the
development of risk estimators for these populations
also requires large population-based, ethnicity and
Fig. 1 The comparison of mean 10-years risk of ASCVD for different age groups as calcualted by Astro-CHARM and PCE
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age-specific data to develop such a tool using both
Astro-CHARM and PCE. Low and middle-income
countries are now overburdened with interventional
procedures like angioplasty, and expensive methods of
secondary prevention. Accurate risk assessment is the
only solution in such resource-poor settings where
primary prevention can be implicated through lifestyle
modifications and statins among high-risk individuals.
However, overestimation and misclassification of an
individual as high risk has its own implications too,
not only at the individual level but also at healthcare
system level, therefore, accuracy of the risk stratifica-
tion modality is crucial.
Strengths and limitations
The biggest strength of the study is the use and com-
parison of both ASCVD estimators in non-cardiac Paki-
stani general population selected from the largest city of
the country with diverse population sub-groups from the
entire country thus providing data facsimile to general
population of Pakistan.
Major limitations of the study lie in the non-
probability snowball sampling technique and study de-
sign where lack of prospective follow-up cannot ensure
the accuracy of these estimates. Furthermore, the data
was taken from an urban setting and implications of the
findings cannot be ascertained on the rural population.











Male 51.9% (178) 76.7% (33) 47.4% (145) 82.5% (66)
Female 48.1% (165) 23.3% (10) 52.6% (161) 17.5% (14)
Weight (kg) 73 ± 15 74 ± 14 74 ± 15 72 ± 13
Height (cm) 162 ± 11 165 ± 10 161 ± 11 166 ± 10
Age (years) 48 ± 7 55 ± 7 47 ± 6 57 ± 6
Hypertensive
Yes 44.6% (153) 53.5% (23) 44.4% (136) 50% (40)
No 55.4% (190) 46.5% (20) 55.6% (170) 50% (40)
Diabetic
Yes 11.1% (38) 53.5% (23) 8.8% (27) 42.5% (34)
No 88.9% (305) 46.5% (20) 91.2% (279) 57.5% (46)
Current Smoker
Yes 11.1% (38) 39.5% (17) 9.2% (28) 33.8% (27)
No 88.9% (305) 60.5% (26) 90.8% (278) 66.2% (53)
Family History of Myocardial infarction
Yes 28.6% (98) 46.5% (20) 32% (98) 25% (20)
No 71.4% (245) 53.5% (23) 68% (208) 75% (60)
Coronary Artery Calcium (Agatston) 9.9 ± 46.42 204.2 ± 546.76 15.5 ± 73.87 93 ± 400.79
Total Cholesterol (mg/dL) 178 ± 37 178 ± 50 175 ± 39 187 ± 37
HDL Cholesterol (mg/dL) 53 ± 39 45 ± 10 53 ± 41 45 ± 11
Systolic Blood Pressure (mmHg) 137 ± 20 155 ± 21 137 ± 20 148 ± 22
Astro-CHARM Astronaut Cardiovascular Health and Risk Modification; PCE Pooled Cohort Equation
Low-Risk = < 7.5% estimated 10 years risk; High-Risk = ≥7.5% estimated 10 years risk
Table 3 Cross tabulation of Pooled Cohort Estimator against
Astro-CHARM for categorizing high risk individuals
Astro-CHARM
Low Risk High Risk
PCE
Low Risk 76.9% (297) 2.3% (9)
High Risk 11.9% (46) 8.8% (34)
Sensitivity 79.07% (95% CI: 63.96 to 89.96%)
Specificity 86.59% (95% CI: 82.52 to 90.01%)
Positive predictive value 42.50% (95% CI: 35.16 to 50.19%)
Negative predictive value 97.06% (95% CI: 94.85 to 98.34%)
Astro-CHARM Astronaut Cardiovascular Health and Risk Modification, PCE
Pooled Cohort Equation, CI Confidence interval
Low-Risk = < 7.5% estimated 10 years risk; High-Risk = ≥7.5% estimated
10 years risk
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Conclusion
Despite the fact that our findings showed substantial dif-
ferences in 10-year risk of ASCVD between Astro-
CHARM and PCE, both calculators can be used to de-
velop a new population and specific risk estimators for
this South Asian sub-population. Our study provides the
first step towards developing a risk assessment guided
decision-making protocol for primary prevention of
ASCVD in this population.
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